Orna Therapeutics
Signal active
Organization
Contact Information
Overview
Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way they treat disease.
The company's proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.
Orna Therapeutics was established in 2019 by Alex Wesselhoeft and Raffaella Squilloni in Cambridge, Massachusetts.
About
Industries
Biotechnology, Pharmaceutical, Medical, Therapeutics
Founded
2019
Employees
101-250
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Orna Therapeutics headquartered in United States, North America, operates in the Biotechnology, Pharmaceutical, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $15.4B in funding across 48 round(s). With a team of 101-250 employees, Orna Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Orna Therapeutics, raised $221.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
3
Investors
3
Lead Investors
0
Total Funding Amount
$321.0M
Details
3
Orna Therapeutics has raised a total of $321.0M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2021 | Early Stage Venture | 80.0M | ||
| 2020 | Seed | 20.0M | ||
| 2022 | Early Stage Venture | 221.0M |
Investors
Orna Therapeutics is funded by 26 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Ansbert Gadicke | - | FUNDING ROUND - Ansbert Gadicke | 221.0M |
| BioImpact | - | FUNDING ROUND - BioImpact | 221.0M |
| Orna Therapeutics | - | FUNDING ROUND - Orna Therapeutics | 221.0M |
| MPM Capital | - | FUNDING ROUND - MPM Capital | 221.0M |
Recent Activity
There is no recent news or activity for this profile.